Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
Biolase, Inc. (NASDAQ: BIOL) is a leading medical device company specializing in the development, manufacturing, marketing, and sales of advanced laser systems used in dentistry and medicine. Based in the United States, the company is recognized globally for its innovative dental laser technologies that enhance dental care by enabling clinicians to perform a wide range of minimally invasive procedures, reducing patient pain, fear, and anxiety typically associated with dental treatments.
Biolase’s flagship products are categorized into two primary groups: Waterlase (all-tissue) systems and Diode (soft-tissue) systems. These products cater to various dental professionals, including general dentists, periodontists, endodontists, and oral surgeons, allowing them to execute procedures ranging from simple restorations to complex surgical interventions. The company’s revenue is predominantly derived from the U.S. market, but its impact is felt worldwide, having sold over 47,700 laser systems across more than 80 countries.
In recent developments, Biolase has expanded its educational initiatives, recognizing the growing demand for knowledge in dental laser technologies. The company launched new courses through its Education.Biolase.com portal, offering both in-person and virtual training through the Waterlase Academy and Epic Diode Academy. This educational expansion includes specialized courses in endodontics, periodontics, pediatric dentistry, and facial esthetics. Notably, Biolase unveiled the Waterlase iPlus Premier Edition at the Chicago Midwinter Meeting 2024, which represents a significant innovation in all-tissue laser systems.
Financially, Biolase has shown resilience amidst challenging market conditions. For the year ending December 31, 2023, the company reported net revenues of $49.2 million, a slight increase compared to the previous year. Despite a decrease in U.S. laser sales, the company saw a 31% increase in U.S. consumables and other revenue. The company is actively optimizing its operations and has undertaken cost-reduction measures, including a workforce reduction projected to save approximately $2.5 million annually.
Looking ahead, Biolase continues to focus on driving the adoption of its dental laser systems and expanding its educational offerings. The company aims to achieve long-term growth and profitability through strategic initiatives and product innovations. For further updates and information, visit www.biolase.com or follow Biolase on various social media platforms.
BIOLASE, Inc. (NASDAQ: BIOL) has entered into an underwriting agreement with Maxim Group LLC to sell 14,000,000 shares of common stock at $1.03 per share. This offering is expected to raise approximately $14.4 million before expenses. The offering's closing is anticipated around February 10, 2021, pending customary closing conditions. This stock sale is part of a shelf registration statement filed with the SEC. BIOLASE is known for its innovative dental laser systems that enhance patient care and clinical outcomes.
BIOLASE, Inc. (NASDAQ: BIOL) has regained compliance with NASDAQ's minimum bid price requirement, confirming its closing bid price has been at least $1.00 for ten consecutive days as of February 3, 2021. This follows a prior notification from NASDAQ in December 2019 regarding a price drop. Consequently, the company has canceled its Special Meeting of Stockholders scheduled for February 16, 2021, and will not pursue a reverse stock split at this time. BIOLASE specializes in developing laser systems for dental and medical applications.
BIOLASE, Inc. (NASDAQ: BIOL) urges stockholders to vote for a proposed 1-for-25 reverse stock split at the reconvened special meeting on February 16, 2021. Insufficient votes were recorded at the initial meeting held on January 22, 2021. The record date for eligible voters changed to January 25, 2021. Stockholders can vote online or by phone to ensure representation. BIOLASE, a leader in dental lasers, has sold over 41,200 laser systems globally, enhancing patient care in dentistry and medicine.
BIOLASE, Inc. (NASDAQ: BIOL) has announced preliminary revenue results for Q4 2020, estimating revenues between $8.2 million and $8.5 million, reflecting a sequential growth of 26-31%. The company reported a cash position of approximately $25 million to support its growth strategy. Notably, 78% of sales came from new users, and U.S. revenue surpassed the previous year's fourth quarter, despite challenges posed by COVID-19. BIOLASE launched initiatives like the Waterlase Endo Academy to enhance its market presence.
On January 12, 2021, BIOLASE announced a partnership with Dental Care Alliance (DCA) to enhance laser adoption in dental practices across the U.S. DCA, a major dental support organization with over 330 affiliated offices, will implement BIOLASE's EpicX and Epic Hygiene lasers, aimed at improving patient care and safety. With more than 100 systems already sold to DCA this year, BIOLASE anticipates widespread deployment throughout 2021. This agreement highlights the growing demand for advanced dental technologies that provide less invasive treatment options.
BIOLASE, Inc. (NASDAQ: BIOL) announced that Todd Norbe and John Beaver will provide an overview of the company at the H.C. Wainwright BIOCONNECT 2021 Investor Conference from January 11-14, 2021. A recorded presentation will be available on-demand starting January 11 at 6:00 a.m. ET on BIOLASE's website. Investors can also arrange virtual one-on-one meetings during the event. BIOLASE is a leader in dental lasers, with over 41,200 systems sold globally, offering innovative laser solutions for various dental procedures.
BIOLASE, a leader in dental lasers, announced a collaboration with BMW Performance Center West for the 2021 Waterlase Exclusive Trial Program. Dentists can participate in a special two-day training and use the Waterlase dental laser at no cost for 45 days. This initiative includes a chance for dentists to win a BMW vehicle lease. The promotional program aims to engage dentists by merging cutting-edge dental technology with a premium driving experience. The event series begins in January 2021.
BIOLASE (NASDAQ: BIOL) will present at the 13th annual LD Micro Main Event investor conference on December 14, 2020, at 9:40 AM PST / 12:40 PM EST. The presentation will be led by President and CEO Todd Norbe and Executive Vice President, CFO and COO John Beaver. This year's conference features a unique format with 10-minute presentations followed by Q&A sessions. This event aims to engage both executives and investors globally.
To learn more, view BIOLASE's profile.
BIOLASE announced the launch of the Waterlase Endo Academy on Nov. 14, 2020, aimed at improving patient outcomes and profitability among endodontists through advanced technology. The academy offers a community for peer-led learning and sharing best practices, featuring mentorship, online meetings, and in-person training. The Waterlase dental laser technology enhances efficiency and patient care, allowing for various dental procedures. BIOLASE has sold over 41,200 laser systems worldwide, underscoring its leadership in dental lasers.
BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental lasers, will take part in the Benchmark Company Discovery One on One Investor Conference on November 18, 2020. CEO Todd Norbe and CFO John Beaver will engage in virtual meetings with institutional investors. This event highlights BIOLASE's strong commitment to advancing dental and medical laser technologies, evidenced by their proprietary systems featuring 259 patented and 41 patent-pending technologies. To date, BIOLASE has sold over 41,500 lasers across more than 80 countries, focusing on delivering superior outcomes with less pain for patients.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
What are the main products offered by Biolase, Inc.?
Where can I find educational resources on Biolase's dental lasers?
How has Biolase performed financially in recent years?
What recent innovations has Biolase introduced?
What is Biolase's strategy for long-term growth?
What markets does Biolase primarily serve?
What is the significance of Biolase's educational initiatives?
How can investors stay informed about Biolase's financial performance?
What are the advantages of using Biolase's laser systems in dentistry?
Where can I find more information about Biolase's products and updates?
